Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study

Xiaofeng GuoJingping Zhao


The relative effectiveness of the atypical antipsychotic drugs and conventional agents in patients with early-stage schizophrenia has not been comprehensively determined. The aim of our study was to evaluate the efficacy and safety of seven antipsychotic drugs for the maintenance treatment in patients with early-stage schizophrenia. In a 12-month open-label, prospective observational, multicenter study, 1,133 subjects with schizophrenia or schizophreniform disorder within 5 years of onset were monotherapy with chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole. The primary measure was the rate of treatment discontinuation for any reason. Secondary outcomes included measures for clinical and functional outcomes and tolerability. The percentage of patients discontinued treatment within 12 months was 41.4% for chlorpromazine, 39.5% for sulpiride, 36.7% for clozapine, 40.2% for risperidone, 39.6% for olanzapine, 46.9% for quetiapine, and 40.2% for aripiprazole, a nonsignificant difference (p = 0.717); there were no significant differences among these seven treatments on discontinuation due to relapse, intolerability, patient decision, or nonadherence (all p values ≥ 0.260). Extrapyramidal sym...Continue Reading


Apr 23, 2013·Frontiers of Medicine·Qingqing XuShengying Qin
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jun 16, 2012·Neuropsychiatric Disease and Treatment·Nilufar Mossaheb, Rainer M Kaufmann
Mar 29, 2014·Current Medical Research and Opinion·Leslie CitromeTony Hebden
Apr 8, 2016·International Journal of Psychiatry in Clinical Practice·Stefano PorcelliAlessandro Serretti
Apr 7, 2016·Nordic Journal of Psychiatry·Oddur IngimarssonEngilbert Sigurdsson
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
Apr 29, 2016·Journal of Medical Economics·Thomas R EinarsonKristel van Impe
Feb 9, 2019·Journal of Medical Economics·Jingping ZhaoJianwei Xuan
Aug 8, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Ziyi Lin, Jianwei Xuan


Jan 1, 1989·The Journal of Nervous and Mental Disease·Joseph P McEvoyL Roth
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyRisperidone-USA-79 Study Group
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanRobert M Hamer
Aug 6, 2003·The American Journal of Psychiatry·Stephen R MarderKaren E Blair
Nov 12, 2003·The International Journal of Neuropsychopharmacology·Siegfried KasperTeresa Pigott
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 29, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·José Luis R MartinEnric Alvarez
Nov 26, 2008·Schizophrenia Research·T Scott StroupCATIE Investigators
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Pei-Xian MaoZhuo-Ji Cai

Related Concepts

Antipsychotic Effect
Atypical Antipsychotic [EPC]
Extrapyramidal Sign
Antipsychotic Agents
Anticholinergic [EPC]

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here